Safety and Effectiveness of the Ultrasonic Propulsion of Kidney Stones
NCT ID: NCT02028559
Last Updated: 2024-02-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
84 participants
INTERVENTIONAL
2014-01-31
2024-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ultrasound to Facilitate Stone Passage
NCT04796792
Ultrasound Imaging of Kidney Stones and Lithotripsy
NCT02214836
A Safety Evaluation of Renal Denervation Using Focused Therapeutic Ultrasound on Patients With Refractory Hypertension
NCT01638195
Feasibility Study of an Enhanced Lithotripsy System in the Treatment of Urinary Stone Disease
NCT03195920
An Intelligent Pressure and Temperature Control Ureteral Soft Scope System for Treating Stones With Infection.
NCT06841523
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In addition to undergoing the investigational procedure, the research activities include the following:
* subjects undergo a pain questionnaire before and after the procedure;
* the subject's skin in the area of probe placement is observed before and after the procedure;
* subjects are contacted once-a-week for 3 weeks to evaluate for potential adverse events, pain medication use, and, if applicable, stone passage;
* subjects are requested to undergo at least one follow-up imaging 4 - 12 weeks post-procedure;
* a review of each subject's medical records is conducted 90-days post-procedure to evaluate for additional effectiveness and safety events.
* Specifically for the residual fragment population (randomized control trial), subjects are contacted every 6 months for 3 years and their charted is reviewed for 5 years for stone growth, symptomatic, unscheduled medical visits, and surgery related to stones.
Subjects that qualify for the trial are recruited into different study arms (referred to as Population groups) based on their type of stone condition (de novo stone versus post-lithotripsy fragment), size of stone (≤ 5 mm or \> 5 mm), and management plan (clinical observation or surgical intervention). The objectives vary based upon the Population group. Subjects may qualify for more than one population group over time and may undergo the investigational procedure up to 4 times total (inclusive of both the left and right-side urinary tracts). Population groups 1-3 has been closed. Therefore, the details provided for this registration is for Population group 4.
1. First-in-Human Population (Closed): This was the initial group of subjects included under this clinical trial. This was a 15-subject feasibility that included a broad range of populations. This feasibility population formulated the basis for expanding the trial into a larger study addressing each population separately. This is encompassed in subject populations 2-5 below.
2. Acute Subject Population (Closed): All subjects undergo the investigational procedure. Subjects undergo the investigational procedure awake and in the clinic or emergency department (ED) setting. To qualify the subject must have clinical imaging confirmation of an obstructing stone with their pain managed and complete a urinalysis to assess infection risk. Ultrasonic propulsion is used with the intent to relieve the obstruction and associated pain. A subset of subjects were exposed to higher amplitude dislodging pulses, in addition to the ultrasonic propulsion pulses.
3. De Novo Subject Population (Closed): Subjects undergo the investigational procedure awake and in the clinic. To qualify the subject must have a de novo stone ≤ 5 mm or, if larger, be scheduled for surgical intervention on the same day. Ultrasonic propulsion is used with the intent to help facilitate stone passage (≤ 5 mm) or demonstrate the ability to move larger stones. In the case of subjects scheduled for URS, the investigative procedure can be conducted concurrently with the standard-of-care procedure (see bullet point #2 above).
4. URS Subject Population (Closed): Subjects undergo the investigational procedure while anesthetized and concurrently undergoing a ureteroscopy guided laser lithotripsy procedure (referred to herein as URS). To qualify the subject must have at least one stone ≤ 20 mm in the largest dimension and be scheduled for surgery. Ultrasonic propulsion may be used to move a de novo stone or stone fragments of varying sizes generated over the course of the URS procedure. Note that since these subjects are anesthetized, a pain questionnaire is not included as part of their protocol.
5. Residual Fragment Population: Subjects undergo the investigational procedure awake and in the clinic setting. To qualify the subject must have at least one residual fragment (≤ 5 mm in largest dimension) identified either on imaging or based on the investigator's interpretation of that imaging. This is a prospective, open-label, multicenter, randomized control trial (RCT) with a treatment arm and control arm. The only difference in protocol between the two arms is that only the treatment group undergoes the investigational procedure and the associated post-procedure pain questionnaire and the post-procedure skin surface inspection. Ultrasonic propulsion is used with the intent to demonstrate the ability of the ultrasonic propulsion device to reposition stones within the human kidney and the subsequent clinical benefit of facilitating stone passage and reducing stone burden to reduce relapse. This is the only population group recruited across more than one site - the UW and the VA Puget Sound Heathcare System.
The final data set collected from the study will be analyzed under two separate statistical analysis plan (SAPs) referred to as NIH SAP and Pivotal SAP.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment with Ultrasonic Propulsion
Subjects receive treatment with the Propulse 1 device. Intervention consists of the non-invasive application of ultrasound to move stones within the kidney and ureter.
Propulse 1
Move kidney stones with Propulse 1 device.
Control
Subject follow same protocol as treatment group but do not receive the ultrasonic propulsion intervention.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Propulse 1
Move kidney stones with Propulse 1 device.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Individuals at least 4-weeks post-lithotripsy procedure
* Individuals with residual stone fragments ≤ 5 mm in largest dimension (individually)
* Individuals being managed with watchful waiting or medical therapy for stones
Exclusion Criteria
* Individuals with non-echogenic stones
* Individuals unable or unwilling to comply with the follow-up requirements
* Individuals with a coagulation abnormality or taking blood thinners or other anticoagulant at clinically significant levels
* Individuals with mobility issues who are unable to comfortably lie for up to 30 minutes or roll from their back to their side
* Individuals belonging to a vulnerable group (pregnant, mentally disabled, physically disabled, prisoner, etc.)
* Individuals who have already received four previous ultrasonic propulsion procedures.
* Individuals who have received an ultrasonic propulsion treatment within the last 4 weeks.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
VA Puget Sound Health Care System
FED
University of Washington
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jonathan Harper, MD
Assistant Professor, Urology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jonathan Harper, MD
Role: PRINCIPAL_INVESTIGATOR
University of Washington
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
VA Puget Sound Health Care System
Seattle, Washington, United States
University of Washington Department of Urology
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Hall MK, Thiel J, Dunmire B, Samson PC, Kessler R, Sunaryo P, Sweet RM, Metzler IS, Chang HC, Gunn M, Dighe M, Anderson L, Popchoi C, Managuli R, Cunitz BW, Burke BH, Ding L, Gutierrez B, Liu Z, Sorensen MD, Wessells H, Bailey MR, Harper JD. First Series Using Ultrasonic Propulsion and Burst Wave Lithotripsy to Treat Ureteral Stones. J Urol. 2022 Nov;208(5):1075-1082. doi: 10.1097/JU.0000000000002864. Epub 2022 Nov 1.
Dai JC, Sorensen MD, Chang HC, Samson PC, Dunmire B, Cunitz BW, Thiel J, Liu Z, Bailey MR, Harper JD. Quantitative Assessment of Effectiveness of Ultrasonic Propulsion of Kidney Stones. J Endourol. 2019 Oct;33(10):850-857. doi: 10.1089/end.2019.0340. Epub 2019 Sep 25.
Harper JD, Cunitz BW, Dunmire B, Lee FC, Sorensen MD, Hsi RS, Thiel J, Wessells H, Lingeman JE, Bailey MR. First in Human Clinical Trial of Ultrasonic Propulsion of Kidney Stones. J Urol. 2016 Apr;195(4 Pt 1):956-64. doi: 10.1016/j.juro.2015.10.131. Epub 2015 Oct 30.
Sorensen MD, Dunmire B, Thiel J, Cunitz BW, Burke BH, Levchak BJ, Popchoi C, Holmes AE, Kucewicz JC, Hall MK, Dighe M, Dai JC, Cormack FC, Liu Z, Bailey MR, Porter MP, Harper JD. Randomized Controlled Trial of Ultrasonic Propulsion-Facilitated Clearance of Residual Kidney Stone Fragments vs Observation. J Urol. 2024 Dec;212(6):811-820. doi: 10.1097/JU.0000000000004186. Epub 2024 Aug 15.
Harper JD, Metzler I, Hall MK, Chen TT, Maxwell AD, Cunitz BW, Dunmire B, Thiel J, Williams JC, Bailey MR, Sorensen MD. First In-Human Burst Wave Lithotripsy for Kidney Stone Comminution: Initial Two Case Studies. J Endourol. 2021 Apr;35(4):506-511. doi: 10.1089/end.2020.0725. Epub 2020 Nov 5.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
STUDY00002746
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.